Business
CLIA Certificate of Compliance
CLIA Certificate of Compliance.
About this update from Verici Dx Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n Verici Dx plc\n \n \n \n \n (\"Verici Dx\" or the \"Company\")\n \n \n \n \n \n \n \n \n \n Verici Dx achieves CLIA Certificate of Compliance for full commercial launch of Tutivia™\n \n \n \n \n Successful CMS review and inspection solidify commercial positioning and\nrepresents a major milestone toward US Medicare reimbursement\n \n \n \n \n \n \n \n \n Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\n announces that it has successfully progressed its Registration status to Compliance Certification by the Centers for Medicare & Medicaid (\"CMS')\n for its commercial clinical operations\n to 45 US states\n .\n This follows the inspection by CMS of the Company's US clinical laboratory based at the Innovation Park in Franklin, Tennessee.\n \n \n \n \n \n The Company now intends to expand commercialisation of its advanced kidney transplant service offerings including Tutivia™.\n This milestone of certification is also a key requirement to obtaining insurance reimbursement coverage under Medicare under the Local Coverage Determination application being submitted this year.\n \n \n \n \n \n The Company launched its first product, Tutivia™, for the detection of early acute rejection in kidney post-transplant patients, in January 2023. This CLIA certification increases the ease of ordering a Tutivia™ test from laboratories at transplant medical centres and provides further validation of Verici's tests and services for transplant clinicians across the United States.\n \n \n \n \n \n The Company will now proceed with its plan towards full accreditation in the remaining five states, including New York, which have further compliance requirements\n . \n \n \n \n \n \n The CLIA certification further exemplifies Verici's commitment to a quality-focused approach to providing advanced kidney transplant diagnostics services to clinicians and patients in need. \n \n \n \n \n \n \n Sara Barrington, CEO of Verici Dx, said:\n \n \n \n \n \"\n \n \n This milestone is an enabling step in our ability to offer our two leading diagnostic tests, Tutivia\n \n ™ and Clarava™, on a national basis to patients and their clinicians. We are well positioned to achieve additional milestones and progress commercial initiatives in 2023 tha...